POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib.

Vachhani P, Yacoub A, Rampal R, Bradley T, Harrison C, Jain T, Kuykendall A, Palandri F, Mascarenhas J, Al-Ali H, Passamonti F, Rothbaum W, Verstovsek S, Heidel FH

Open source

DOI: 10.1080/14796694.2026.2638989
Published: 2026 Mar
Container: Future oncology (London, England)
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/14796694.2026.2638989,
  title = {POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib.},
  author = {Vachhani P and Yacoub A and Rampal R and Bradley T and Harrison C and Jain T and Kuykendall A and Palandri F and Mascarenhas J and Al-Ali H and Passamonti F and Rothbaum W and Verstovsek S and Heidel FH},
  year = {2026},
  journal = {Future oncology (London, England)},
  doi = {10.1080/14796694.2026.2638989},
  url = {https://doi.org/10.1080/14796694.2026.2638989}
}

RIS

TY  - JOUR
TI  - POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib.
AU  - Vachhani P
AU  - Yacoub A
AU  - Rampal R
AU  - Bradley T
AU  - Harrison C
AU  - Jain T
AU  - Kuykendall A
AU  - Palandri F
AU  - Mascarenhas J
AU  - Al-Ali H
AU  - Passamonti F
AU  - Rothbaum W
AU  - Verstovsek S
AU  - Heidel FH
PY  - 2026
JO  - Future oncology (London, England)
DO  - 10.1080/14796694.2026.2638989
UR  - https://doi.org/10.1080/14796694.2026.2638989
ER  -

APA

P, V., A, Y., R, R., T, B., C, H., T, J., A, K., F, P., J, M., H, A., F, P., W, R., S, V., & FH, H. (2026). POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib.. Future oncology (London, England). https://doi.org/10.1080/14796694.2026.2638989

Source records

pubmed · retrieved 2026-09-26T10:13:44.220Z